.Pharmacolibrary.Drugs.N_NervousSystem.N07X_OtherNervousSystemDrugs.N07XX19_SodiumPhenylbutyrateAndU.SodiumPhenylbutyrateAndU .Pharmacolibrary.Drugs.N_NervousSystem.N07X_OtherNervousSystemDrugs.N07XX19_SodiumPhenylbutyrateAndU.SodiumPhenylbutyrateAndU| name: | SodiumPhenylbutyrateAndUrsodoxicoltaurine | |
| ATC code: | N07XX19 | route: | orally |
| compartments: | 1 | |
| dosage: | 3000 | mg |
| volume of distribution: | 0.2 | L |
| clearance: | 0.1 | L/h/kg |
| other parameters in model implementation | ||
Sodium phenylbutyrate and ursodoxicoltaurine is a fixed-dose combination therapy under investigation for the treatment of amyotrophic lateral sclerosis (ALS). It combines sodium phenylbutyrate, a histone deacetylase inhibitor that may modulate protein homeostasis, with tauroursodeoxycholic acid (as ursodoxicoltaurine), a neuroprotective bile acid derivative. This combination is used as an experimental/orphan therapy and is not widely approved for general use but has received conditional or fast-track designations in certain countries for ALS.
No published clinical pharmacokinetic models available as of June 2024 for the sodium phenylbutyrate and ursodoxicoltaurine fixed-dose combination; estimates provided based on individual component parameters from published sources in healthy adults.